Multiple sclerosis drug pipeline
http://dbpedia.org/resource/Multiple_sclerosis_drug_pipeline
There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and found to be adequate. Pharmaceuticals already on the market, such as Vitamin D do not have to and may never have had do so, and the financial incentives to do so are relatively insignificant. Thus lack of approval of such drugs implies neither efficacy nor lack of efficacy.
rdf:langString
rdf:langString
Multiple sclerosis drug pipeline
xsd:integer
51173038
xsd:integer
1080555924
rdf:langString
There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and found to be adequate. Pharmaceuticals already on the market, such as Vitamin D do not have to and may never have had do so, and the financial incentives to do so are relatively insignificant. Thus lack of approval of such drugs implies neither efficacy nor lack of efficacy. In general, novel pharmaceuticals cannot enter a market without government approval; standards and political influences vary.
xsd:nonNegativeInteger
82739